(Total Views: 204)
Posted On: 10/19/2019 10:44:21 AM
Post# of 36541
Re: Paul Jackson #7503
Olaregen needs to get the product in the hands of wound care and other docs.
I know they contracted with AvKare for the VA line of business. This makes sense as there is large population of patients and it is relatively easy to get the reps> docs educated and distributing the product to a system already familiar with AvKare.
Private practice docs throughout the country is a whole other deal. I assume the Oct 1 launch announcement of the product means it will be implemented as funds allow.
Can we accomplish this as an OTC stock?
I know they contracted with AvKare for the VA line of business. This makes sense as there is large population of patients and it is relatively easy to get the reps> docs educated and distributing the product to a system already familiar with AvKare.
Private practice docs throughout the country is a whole other deal. I assume the Oct 1 launch announcement of the product means it will be implemented as funds allow.
Can we accomplish this as an OTC stock?
(1)
(0)Scroll down for more posts ▼
